Current drug therapy for rheumatoid arthritis

Journal of Orthopaedic Science

Volumn 8, Issue 2, 2003, Pages 259-263

  Kawai, Shinichi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biologic agents; New immunosuppressants; Rheumatoid arthritis; Selective COX 2 inhibitors; Therapeutics

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ANTIRHEUMATIC AGENT; ARACHIDONIC ACID; AZATHIOPRINE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DICLOFENAC; ETANERCEPT; ETIDRONIC ACID; ETODOLAC; GLUCOCORTICOID; GOLD; INDOMETACIN; INFLIXIMAB; LEFLUNOMIDE; MELOXICAM; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PROSTAGLANDIN SYNTHASE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RISEDRONIC ACID; ROFECOXIB; SALAZOSULFAPYRIDINE; TACROLIMUS; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; EDEMA; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERTENSION; NONHUMAN; OSTEOPOROSIS; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; TUBERCULOSIS;

EID: 0037266930     PISSN: 09492658     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007760300045     Document Type: Conference Paper

References (29)

1. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11.
2. Asanuma Y, Nagai K, Kato M, et al. Weekly pulse therapy of methotrexate improves survival compared with daily administration in MRL/lpr mice. Eur J Pharmacol 2002;435:253-8.
3. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 2000;343:1520-8.
5. Chrousos GP. A new "new" syndrome in the new world: is multiple postreceptor steroid hormone resistance due to a coregulator defect? J Clin Endocrinol Metab 1999;84:4454-64.
6. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-18.
7. Di Rosa M, Flower RJ, Hirata F, et al. Anti-phospholipase proteins. Prostaglandins 1984;28:441-2.
8. Furst DE, Saag K, Fleischmann MR, et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum 2002;46:2020-8.
9. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev 2002;82:331-71.
10. Kawai S. Cyclooxygenase selectivity and the risk of gastrointestinal complications of various nonsteroidal anti-inflammatory drugs: a clinical consideration. Inflamm Res 1998;47(suppl 2): S102-6.
11. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
12. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis: the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995;333: 142-6.
13. Kojima F, Naraba H, Sasaki Y, et al. Coexpression of microsomal prostaglandin E synthase with cyclooxygenase-2 in human rheumatoid synovial cells. J Rheumatol 2002;29:1836-42.
14. Kudo I, Murakami M. Diverse functional coupling of prostanoid biosynthetic enzymes in various cell types. Adv Exp Med Biol 1999;469:29-35.
15. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1999;266:12866-72.
16. Kusunoki N, Yamazaki R, Kawai S. Induction of apoptpsis in rheumatoid synovial fibroblasts by celecoxib, not by other selective cyclooxygenase-2 inhibitors. Arthritis Rheum 2002;46: 3159-67.
17. Lee HJ, Soliman MR. Anti-inflammatory steroids without pituitary-adrenal suppression. Science 1982;215:989-91.
18. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343: 1594-602.
19. Mizushima Y. Lipid microspheres as novel drug carriers. Drugs Exp Clin Res 1985;11:595-600.
20. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
21. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal antiinflammatory drugs. Am J Med 2001;111:64-7.
22. Schnitzer TJ, Truitt K, Fleischmann R, et al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis: Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clin Ther 1999;21:1688-702.
23. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the Celecoxib Longterm Arthritis Safety Study (CLASS): a randomized controlled trial. JAMA 2000;284:1247-55.
24. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randmized controlled trial. JAMA 1999;282:1921-8.
25. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159:2542-50.
26. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995;99: 235-42.
27. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971;231:232-5.
28. Xie WL, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1999;88: 2692-6.
29. Yamazaki R, Kusunoki N, Matsuzaki T, et al. Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor γ in rheumatoid synovial cells. J Pharmacol Exp Ther 2002;302:18-25.